External Beam and Radioligand Radiotherapy for mCRPC

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with Lutetium-177 (¹⁷⁷Lu-PSMA) is an established treatment for metastatic prostate cancer. Administered intravenously, it enables targeted irradiation of PSMA-expressing tumor cells. However, 30-50% of patients derive limited benefit. This variability could be partly explained by heterogeneity in delivered dose across lesions, leading to under-treatment of certain metastases. The addition of targeted external beam radiotherapy (EBRT) may compensate for this underdosing by delivering a precise dose to insufficiently irradiat

Trial Details

NCT ID
NCT07354594
Phase
PHASE2
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy
  • Standard of care 177Lutetium-PSMA
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Receiving 177Lu-PSMA for mCRPC
  • Presence of a discernible metastatic burden suitable for EBRT
  • Receiving bone protective therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →